NASDAQ:ADAP
Adaptimmune Therapeutics plc Stock News
$1.14
+0.130 (+12.87%)
At Close: Apr 23, 2024
Adaptimmune Therapeutics' (ADAP) CEO Adrian Rawcliffe on Q1 2022 Results - Earnings Call Transcript
01:57pm, Monday, 09'th May 2022
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Juli Miller – Head-Investor Relations Adrian Rawcliffe – Chief Executive Of
New Strong Sell Stocks for April 26th
09:02am, Tuesday, 26'th Apr 2022
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
New Strong Sell Stocks for April 22nd
10:32am, Friday, 22'nd Apr 2022
BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
03:43pm, Tuesday, 19'th Apr 2022
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday
04:40pm, Monday, 11'th Apr 2022
Investors were not pleased that the company is preparing for a stock sale.
New Strong Sell Stocks for April 11th
12:48pm, Monday, 11'th Apr 2022
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2022.
New Strong Sell Stocks for March 25th
09:02am, Friday, 25'th Mar 2022
DDD, ADAP, and ADV have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2022.
New Strong Sell Stocks for March 17th
12:12pm, Thursday, 17'th Mar 2022 Zacks Investment Research
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.
New Strong Sell Stocks for March 17th
09:47am, Thursday, 17'th Mar 2022
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.
Adaptimmune Therapeutics Plc''s (ADAP) CEO Adrian Rawcliffe On Q4 2021 Results - Earnings Call Transcript
04:16pm, Monday, 14'th Mar 2022 Seeking Alpha
Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left?
03:31pm, Monday, 14'th Mar 2022 Zacks Investment Research
Growing revenues, strong performances exhibited by segments, numerous acquisitions and sturdy financial standing continue to drive Tenet Healthcare (THC).
Thinking about buying stock in Turquoise Hill Resources, Mullen Automotive, Frontier Group, Adaptimmune Therapeutics, or Nokia?
01:31pm, Monday, 14'th Mar 2022 Kwhen FinanceAdaptimmune Therapeutics plc's (ADAP) CEO Adrian Rawcliffe on Q4 2021 Results - Earnings Call Transcript
12:16pm, Monday, 14'th Mar 2022
Adaptimmune Therapeutics plc's (ADAP) CEO Adrian Rawcliffe on Q4 2021 Results - Earnings Call Transcript
Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q1 By Investing.com
12:14pm, Monday, 14'th Mar 2022 Investing.com
Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q1
Adaptimmune Therapeutics: Q4 Earnings Insights
12:12pm, Monday, 14'th Mar 2022 Benzinga
Adaptimmune Therapeutics (NASDAQ: ADAP ) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Adaptimmune Therapeutics missed estimated earnings by 128.57%, reporting an EPS of $-0.04 versus … Full story available on Benzinga.com
